Comparatively few biologic drugs are making it to the market, and many of those are for rare diseases, writes Nick Terrett, chief science officer at Ensemble Therapeutics. Part of the reason is the difficulty of developing biologic drugs, but the industry could use a paradigm shift in how it develops drugs, Terrett writes. Combining small-molecules and biologics could create a new therapy option, the macrocycle, he writes.
Creating therapies with macrocycles could spur biologics development
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||